PreferredStockChannel
Cyclacel Pharmaceuticals Inc | 6% Convertible Exchangeable Preferred Stock (CYCCP)

Prospectus excerpt:   Xcyte Therapies, Inc. is offering 2,600,000 shares of 6% convertible exchangeable preferred stock, which is referred to in this prospectus as Ùconvertible preferred stock.ˆ Dividends will be cumulative from the date of original issue at the annual rate of 6% of the liquidation preference of the convertible preferred stock, payable quarterly on the first day of February, May, August and November, commencing February 1, 2005. Any dividends must be declared by board of directors and must come from funds that are legally available for dividend payments. You may convert each share of the convertible preferred stock into approximately 4.2553 shares of our common stock based on the initial conversion price of $2.35, subject to certain adjustments. Company may elect to automatically convert the convertible preferred stock into common stock if the closing price of common stock has exceeded $3.53 which is 150% of the conversion price of the convertible preferred stock, for at least 20 trading days during any 30-day trading period, ending within five trading days prior to notice of automatic conversion. If company elects to automatically convert, or you elect to voluntarily convert, some or all of the convertible preferred stock into common stock prior to November 3, 2007, company will make an additional payment on the convertible preferred stock equal to the aggregate amount of dividends that would have been payable on the convertible preferred stock through and including November 3, 2007, less any dividends already paid on the convertible preferred stock. Company may elect to redeem the convertible preferred stock on or after November 6, 2007 on the terms described in this prospectus. At company's option, they may exchange the convertible preferred stock in whole, but not in part, on any dividend payment date beginning on November 1, 2005 for 6% convertible subordinated debentures. If they elect to exchange the convertible preferred stock for debentures, the exchange rate will be $10 principal amount of debentures for each share of the convertible preferred stock. The debentures, if issued upon exchange of the convertible preferred stock, will mature 25 years after the exchange date and will have terms substantially similar to those of the preferred stock. The convertible preferred stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.

Full Prospectus PDF », Secondary Prospectus PDF », CYCC Page »

Redeemable?:Yes
Call Date:11/6/2007 (Now Trading Post Call Date)
Perpetual?:Yes
Cumulative?:Yes
Conversion Ratio:4.2553
Conversion Price:$2.35
Shares Offered:2,600,000
Overallotment:390,000
Liquidation Preference:$10.00
Recent Market Price:$18.20
Premium to Liquidation Preference:
(More Preferreds Trading at a Premium »)
$8.20 (82.00%)
Annualized Dividend:0.6
Recent Ex-Date:1/19/2024
Current Yield:3.30%
Original Coupon:6.00%
Pay Period:Quarterly
Pay Dates:1-Feb, 1-May, 1-Aug, 1-Nov
CDx3 Compliance Rating: Learn CYCCP's Rating
Cyclacel Pharmaceuticals is a biopharmaceutical company engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin Dependent Kinase 2/9 (CDK2/9) inhibitor, in solid tumors and hematological malignancies. CDKs also provide pivotal functions in the regulation of transcription, DNA repair and metastatic spread. The anti-mitotic program is evaluating plogosertib, a polo-like kinase, or PLK inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle.

Preferred: CYCCP


Open the CYCC Information Page »
Name: 
Cyclacel Pharmaceuticals Inc
Website: 
www.cyclacel.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding CYCC: 
1 (see which ones)
Total Market Value Held by ETFs: 
$11,592
Total Market Capitalization: 
$3,000,000
% of Market Cap. Held by ETFs: 
0.39%

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Cyclacel Pharmaceuticals Inc | 6% Convertible Exchangeable Preferred Stock (CYCCP) Information Page | Preferred Stock Channel | www.PreferredStockChannel.com

Copyright © 2010 - 2024, All Rights Reserved Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.